Medical Management of Primary Hyperparathyroidism

Overview

Journal Arch Endocrinol Metab

Specialty Endocrinology

Date 2022 Nov 16

PMID 36382758

Authors

Francisco Bandeira

Janiere de Moura Nobrega

Lucian Batista de Oliveira

John Bilezikian

Affiliations

Soon will be listed here.

Abstract

Primary hyperparathyroidism (PHPT) is an endocrine disorder resulting from the hyperfunction of one or more parathyroid glands, with hypersecretion of parathyroid hormone (PTH). It can be managed by parathyroidectomy (PTX) or non-surgically. Medical therapy with pharmacological agents is an alternative for those patients with asymptomatic PHPT who meet guidelines for surgery but are unable or unwilling to undergo PTX. In this review, we focus upon these non-surgical aspects of PHPT management. We emphasize the most studied and widely used pharmacological alternatives: bisphosphonates, denosumab, cinacalcet and hormone therapy, in addition to combined therapy. We also address the relevant aspects of perioperative management.

Citing Articles

Correlation between parathyroid adenoma volume and perioperative outcomes in primary hyperparathyroidism: Does the size matter?.

Fiore A, Eschlbock S, Carlen C, Lazaridis I, Lalos A, Droeser R Updates Surg. 2025; .

PMID: 39883321 DOI: 10.1007/s13304-025-02086-4.

Turning Points in Cross-Disciplinary Perspective of Primary Hyperparathyroidism and Pancreas Involvements: Hypercalcemia-Induced Pancreatitis, Gene-Related Tumors, and Insulin Resistance.

Carsote M, Nistor C, Gheorghe A, Sima O, Trandafir A, Nistor T Int J Mol Sci. 2024; 25(12).

PMID: 38928056 PMC: 11203827. DOI: 10.3390/ijms25126349.

Neuroendocrine Parathyroid Tumors: Quality of Life in Patients with Primary Hyperparathyroidism.

Carsote M, Nistor C, Stanciu M, Popa F, Cipaian R, Popa-Velea O Biomedicines. 2023; 11(7).

PMID: 37509698 PMC: 10377520. DOI: 10.3390/biomedicines11072059.

References

Rossini M, Gatti D, Isaia G, Sartori L, Braga V, Adami S . Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism. J Bone Miner Res. 2001; 16(1):113-9. DOI: 10.1359/jbmr.2001.16.1.113. View

Khan A, Bilezikian J, Kung A, Ahmed M, Dubois S, Ho A . Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial. J Clin Endocrinol Metab. 2004; 89(7):3319-25. DOI: 10.1210/jc.2003-030908. View

Ross A, Manson J, Abrams S, Aloia J, Brannon P, Clinton S . The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab. 2010; 96(1):53-8. PMC: 3046611. DOI: 10.1210/jc.2010-2704. View

Orr-Walker B, Evans M, Clearwater J, Horne A, Grey A, Reid I . Effects of hormone replacement therapy on bone mineral density in postmenopausal women with primary hyperparathyroidism: four-year follow-up and comparison with healthy postmenopausal women. Arch Intern Med. 2000; 160(14):2161-6. DOI: 10.1001/archinte.160.14.2161. View

Bilezikian J, Cusano N, Khan A, Liu J, Marcocci C, Bandeira F . Primary hyperparathyroidism. Nat Rev Dis Primers. 2016; 2:16033. PMC: 5385896. DOI: 10.1038/nrdp.2016.33. View

Bandeira L, Bilezikian J . Primary Hyperparathyroidism. F1000Res. 2016; 5. PMC: 4963029. DOI: 10.12688/f1000research.7039.1. View

Shah V, Shah C, Bhadada S, Rao D . Effect of 25 (OH) D replacements in patients with primary hyperparathyroidism (PHPT) and coexistent vitamin D deficiency on serum 25(OH) D, calcium and PTH levels: a meta-analysis and review of literature. Clin Endocrinol (Oxf). 2014; 80(6):797-803. DOI: 10.1111/cen.12398. View

Ryhanen E, Koski A, Loyttyniemi E, Valimaki M, Kiviniemi U, Schalin-Jantti C . Postoperative zoledronic acid for osteoporosis in primary hyperparathyroidism: a randomized placebo-controlled study. Eur J Endocrinol. 2021; 185(4):515-524. DOI: 10.1530/EJE-21-0322. View

Miyaoka D, Imanishi Y, Kato E, Toi N, Nagata Y, Kurajoh M . Effects of denosumab as compared with parathyroidectomy regarding calcium, renal, and bone involvement in osteoporotic patients with primary hyperparathyroidism. Endocrine. 2020; 69(3):642-649. DOI: 10.1007/s12020-020-02401-6. View

10.

Silverberg S, Clarke B, Peacock M, Bandeira F, Boutroy S, Cusano N . Current issues in the presentation of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. J Clin Endocrinol Metab. 2014; 99(10):3580-94. PMC: 5393491. DOI: 10.1210/jc.2014-1415. View

11.

Tournis S, Fakidari E, Dontas I, Liakou C, Antoniou J, Galanos A . Effect of parathyroidectomy versus risedronate on volumetric bone mineral density and bone geometry at the tibia in postmenopausal women with primary hyperparathyroidism. J Bone Miner Metab. 2013; 32(2):151-8. DOI: 10.1007/s00774-013-0473-6. View

12.

Eller-Vainicher C, Palmieri S, Cairoli E, Goggi G, Scillitani A, Arosio M . Protective Effect of Denosumab on Bone in Older Women with Primary Hyperparathyroidism. J Am Geriatr Soc. 2018; 66(3):518-524. DOI: 10.1111/jgs.15250. View

13.

Walker M, Cong E, Lee J, Kepley A, Zhang C, McMahon D . Vitamin D in Primary Hyperparathyroidism: Effects on Clinical, Biochemical, and Densitometric Presentation. J Clin Endocrinol Metab. 2015; 100(9):3443-51. PMC: 4570160. DOI: 10.1210/jc.2015-2022. View

14.

Bandeira F, Griz L, Chaves N, Carvalho N, Borges L, Lazaretti-Castro M . Diagnosis and management of primary hyperparathyroidism--a scientific statement from the Department of Bone Metabolism, the Brazilian Society for Endocrinology and Metabolism. Arq Bras Endocrinol Metabol. 2013; 57(6):406-24. DOI: 10.1590/s0004-27302013000600002. View

15.

Faggiano A, Di Somma C, Ramundo V, Severino R, Vuolo L, Coppola A . Cinacalcet hydrochloride in combination with alendronate normalizes hypercalcemia and improves bone mineral density in patients with primary hyperparathyroidism. Endocrine. 2011; 39(3):283-7. DOI: 10.1007/s12020-011-9459-0. View

16.

Choe H, Koo B, Yi K, Kong S, Kim J, Shin C . Skeletal effects of combined bisphosphonates treatment and parathyroidectomy in osteoporotic patients with primary hyperparathyroidism. J Bone Miner Metab. 2021; 40(2):292-300. DOI: 10.1007/s00774-021-01279-2. View

17.

Khan A, Bilezikian J, Kung A, Dubois S, Standish T, Syed Z . Alendronate therapy in men with primary hyperparathyroidism. Endocr Pract. 2009; 15(7):705-13. PMC: 4357232. DOI: 10.4158/EP08178.ORR. View

18.

Rothe H, Liangos O, Biggar P, Petermann A, Ketteler M . Cinacalcet treatment of primary hyperparathyroidism. Int J Endocrinol. 2011; 2011:415719. PMC: 3065008. DOI: 10.1155/2011/415719. View

19.

Orr L, Zhou H, Zhu C, Haigh P, Adams A, Yeh M . Skeletal effects of combined medical and surgical management of primary hyperparathyroidism. Surgery. 2019; 167(1):144-148. DOI: 10.1016/j.surg.2019.04.059. View

20.

Marcocci C, Chanson P, Shoback D, Bilezikian J, Fernandez-Cruz L, Orgiazzi J . Cinacalcet reduces serum calcium concentrations in patients with intractable primary hyperparathyroidism. J Clin Endocrinol Metab. 2009; 94(8):2766-72. PMC: 3214593. DOI: 10.1210/jc.2008-2640. View